Clinical trial
Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic…
NCT00084565 · Fox Chase Cancer Center, Other · Withdrawn
Key facts
| NCT number | NCT00084565 |
|---|---|
| Title | Paclitaxel, Topotecan, and Estramustine in Treating Patients With Metastatic Hormone-Refractory Prostate Cancer |
| Official title | Phase II Study of the Activity of Weekly Paclitaxel, Topotecan Plus Oral Estramustine Phosphate in Metastatic Hormone-Refractory Prostate Carcinoma |
| Lead sponsor | Fox Chase Cancer Center, Other |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | estramustine phosphate sodium, paclitaxel, topotecan hydrochloride |
| Enrollment | 0 |
| Start date | Nov 1, 2003 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | Jun 11, 2004 |
| Last update posted | Jul 10, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: